Skip to main content
SpringerLink
Log in

Principles of Chemotherapy in Older Adults

  • Living reference work entry
  • First Online:
Geriatric Oncology

  • 120 Accesses

Abstract

The aging of the population and the resultant increase in older patients with cancer make the study of this vulnerable group an important focus of cancer care. Older patients are the largest consumer of pharmaceuticals and have the highest incidence of drug toxicity and adverse events. It is critical for clinicians to have adequate information regarding these therapeutic issues. This chapter will discuss some basics of pharmacology and aging and drug metabolism of specific agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Aita P, Robieux I, Sorio R, Tumolo S, Corona G, Cannizzaro R, Colussi AM, Boiocchi M, Toffoli G. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol. 1999;43(4):287–94.

    Article  CAS  PubMed  Google Scholar 

  • Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol. 1997;24(5 Suppl 17):87–90.

    CAS  Google Scholar 

  • Aoki S, Tsukada N, Nomoto N, Maruyama S, Takahashi M, Moriyama Y, Shibata A, Aizawa Y. Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res. 1998;17(4):465–70.

    CAS  PubMed  Google Scholar 

  • Aparicio T, Desrame J, Lecomte T, Mitry E, Belloc J, Etienney I, Montembault S, Vayre L, Locher C, Ezenfis J, Artru P, Mabro M, Dominguez S. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer. 2003;89(8):1439–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Audisio RA, Pope D, Ramesh HS, Gennari R, van Leeuwen BL, West C, Corsini G, Maffezzini M, Hoekstra HJ, Mobarak D, Bozzetti F, Colledan M, Wildiers H, Stotter A, Capewell A, Marshall E. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol. 2008;65(2):156–63. S1040-8428(07)00232-6 [pii]. https://doi.org/10.1016/j.critrevonc.2007.11.001.

    Article  CAS  PubMed  Google Scholar 

  • Balducci L, Beghe C. Pharmacology of chemotherapy in the older cancer patient. Cancer Control. 1999;6(5):466–70.

    Article  CAS  PubMed  Google Scholar 

  • Bellera CA, Rainfray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M, Soubeyran PL. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166–72. https://doi.org/10.1093/annonc/mdr587.

    Article  CAS  PubMed  Google Scholar 

  • Berardi R, Saladino T, Mari D, Silva RR, Scartozzi M, Verdecchia L, Onofri A, Cascinu S. Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy. Tumori. 2005;91(6):463–6.

    CAS  PubMed  Google Scholar 

  • Biganzoli L, Robert C, Alessandro M, Anne H, Matti A, Patrick T, Giuseppe M, Jan B, Martine P. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx trade mark) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol. 2006;61:84–9.

    Article  PubMed  Google Scholar 

  • Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine- based methodologies. Eur J Cancer. 2002;38(1):11–6.

    Article  CAS  PubMed  Google Scholar 

  • Camaggi CM, Strocchi E, Martoni A, Angelelli B, Comparsi R, Pannuti F. Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients. Drugs Exp Clin Res. 1985;11(4):285–94.

    CAS  PubMed  Google Scholar 

  • Camidge R, Reigner B, Cassidy J, Grange S, Abt M, Weidekamm E, Jodrell D. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol. 2005;23(21):4719–25.

    Article  CAS  PubMed  Google Scholar 

  • Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV, Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: the cancer prevention study-II nutrition cohort. J Clin Oncol. 2012;30(1):42–52. https://doi.org/10.1200/jco.2011.38.0287.

    Article  PubMed  Google Scholar 

  • Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566–75.

    Article  CAS  PubMed  Google Scholar 

  • Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S, Cannone M. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the southern Italy cooperative oncology group trial 0108. Cancer. 2005;104(2):282–9.

    Article  CAS  PubMed  Google Scholar 

  • Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1988;25:1–9.

    Article  Google Scholar 

  • Dees EC, O’Reilly S, Goodman SN, Sartorius S, Levine MA, Jones RJ, Grochow LB, Donehower RC, Fetting JH. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Investig. 2000;18(6):521–9.

    Article  CAS  Google Scholar 

  • Delea TE, Vera-Llonch M, Edelsberg JS, McGarry L, Anton S, Ulcickas-Yood M, Oster G. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health. 2002;5(1):35–43.

    Article  PubMed  Google Scholar 

  • Donelli MG, Zucchetti M, Munzone E, D’Incalci M, Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer. 1998;34(1):33–46.

    Article  CAS  PubMed  Google Scholar 

  • Dorr RT, Von Hoff DD. Cancer chemotherapy handbook. 2nd ed. Norwalk: Appleton & Lange; 1994.

    Google Scholar 

  • El Cheikh J, Kfoury E, Calmels B, Lemarie C, Stoppa AM, Bouabdallah R, Coso D, Schiano De Collela JM, Ladaique P, Gastaut JA, Mohty M, Chabannon C, Blaise D. Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2011;4(1):30–6. https://doi.org/10.5144/1658-3876.2011.30 [pii].

    Article  PubMed  Google Scholar 

  • Extermann M (2004) Pharmacokinetics of weekly docetaxel in elderly patients: how well can it be predicted? . Personal Communication.

    Google Scholar 

  • Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582–7.

    Article  CAS  PubMed  Google Scholar 

  • Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol. 2000;18(8):1709–17.

    Article  CAS  PubMed  Google Scholar 

  • Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ 3rd, Balducci L. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer. 2012;118(13):3377–86. https://doi.org/10.1002/cncr.26646.

    Article  PubMed  Google Scholar 

  • Feliu J, Escudero P, Llosa F, Bolanos M, Vicent JM, Yubero A, Sanz-Lacalle JJ, Lopez R, Lopez-Gomez L, Casado E, Gomez-Reina MJ, Gonzalez-Baron M. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol. 2005;23(13):3104–11.

    Article  CAS  PubMed  Google Scholar 

  • Feliu J, Salud A, Escudero P, Lopez-Gomez L, Bolanos M, Galan A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, Gonzalez-Baron M. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 2006;94(7):969–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Kohne CH. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15(9):1330–8.

    Article  CAS  PubMed  Google Scholar 

  • Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.

    Article  CAS  PubMed  Google Scholar 

  • Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003;21(5):807–14.

    Article  CAS  PubMed  Google Scholar 

  • Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D’Andrea G, Lake D, Norton L, Hudis CA, Traina TA. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2011;131(1):111–6. https://doi.org/10.1007/s10549-011-1749-y.

    Article  CAS  PubMed  Google Scholar 

  • Garst J, Buller R, Lane S, Crawford J. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clin Lung Cancer. 2005;7(3):190–6.

    Article  CAS  PubMed  Google Scholar 

  • Gauvin A, Pinguet F, Culine S, Astre C, Cupissol D, Bressolle F. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. Cancer Chemother Pharmacol. 2002;49(1):48–56.

    Article  CAS  PubMed  Google Scholar 

  • Gibson TM, Park Y, Robien K, Shiels MS, Black A, Sampson JN, Purdue MP, Beane Freeman LE, Andreotti G, Weinstein SJ, Albanes D, Fraumeni JF, Curtis RE, Berrington de Gonzalez A, Morton LM. Body mass index and risk of second obesity-associated cancers after colorectal cancer: a pooled analysis of prospective cohort studies. J Clin Oncol. 2014;32(35):4004–11. https://doi.org/10.1200/jco.2014.56.8444.

    Article  PubMed  PubMed Central  Google Scholar 

  • Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24(25):4085–91.

    Article  CAS  PubMed  Google Scholar 

  • Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6(4):1205–18.

    CAS  PubMed  Google Scholar 

  • Haller DG, Catalano PJ, Macdonald JS, O’Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of intergroup 0089. J Clin Oncol. 2005;23(34):8671–8.

    Article  PubMed  Google Scholar 

  • Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res. 2000;6(4):1255–8.

    CAS  PubMed  Google Scholar 

  • Hurria A, Cohen HJ, Extermann M. Geriatric oncology research in the cooperative groups: a report of a SIOG special meeting. J Geriatr Oncol. 2010;1(1):40–4. https://doi.org/10.1016/j.jgo.2010.03.005.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hurria A, Cirrincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, Schmieder L, Ansari R, Tew WP, Weckstein D, Kirshner J, Togawa K, Hansen K, Katheria V, Stone R, Galinsky I, Postiglione J, Cohen HJ. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011a;29(10):1290–6. https://doi.org/10.1200/JCO.2010.30.6985.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011b;29(25):3457–65. JCO.2011.34.7625 [pii]. https://doi.org/10.1200/JCO.2011.34.7625.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, Muss HB, Schilsky RL, Ferrell B, Extermann M, Schmader KE, Mohile SG, Cancer, Aging Research G. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587–94. https://doi.org/10.1200/JCO.2013.55.0418.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hurria A, Levit LA, Dale W, Mohile SG, Muss HB, Fehrenbacher L, Magnuson A, Lichtman SM, Bruinooge SS, Soto-Perez-de-Celis E, Tew WP, Postow MA, Cohen HJ. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J Clin Oncol. 2015; https://doi.org/10.1200/JCO.2015.63.0319.

    Article  PubMed  Google Scholar 

  • Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer- treatment trials. N Engl J Med. 1999;341(27):2061–7.

    Article  CAS  PubMed  Google Scholar 

  • Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant. 2006;37(10):917–22.

    Article  CAS  PubMed  Google Scholar 

  • Kelly CM, Shahrokni A. Moving beyond Karnofsky and ECOG performance status assessments with new technologies. J Oncol. 2016;2016:6186543. https://doi.org/10.1155/2016/6186543.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kenis C, Decoster L, Van Puyvelde K, De Greve J, Conings G, Milisen K, Flamaing J, Lobelle JP, Wildiers H. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol. 2014;32(1):19–26. https://doi.org/10.1200/JCO.2013.51.1345.

    Article  PubMed  Google Scholar 

  • Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL. Modernizing eligibility criteria for molecularly driven trials. J Clin Oncol. 2015;33(25):2815–20. https://doi.org/10.1200/JCO.2015.62.1854.

    Article  CAS  PubMed  Google Scholar 

  • Klepin HD, Hurd DD. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions? Bone Marrow Transplant. 2006;38(9):585–92. 1705486 [pii]. https://doi.org/10.1038/sj.bmt.1705486.

    Article  CAS  PubMed  Google Scholar 

  • Korc-Grodzicki B, Sun SW, Zhou Q, Iasonos A, Lu B, Root JC, Downey RJ, Tew WP. Geriatric assessment as a predictor of delirium and other outcomes in elderly patients with cancer. Ann Surg. 2014. https://doi.org/10.1097/SLA.0000000000000742.

    Article  PubMed  Google Scholar 

  • Korc-Grodzicki B, Sun SW, Zhou Q, Iasonos A, Lu B, Root JC, Downey RJ, Tew WP. Geriatric assessment as a predictor of delirium and other outcomes in elderly patients with cancer. Ann Surg. 2015;261(6):1085–90. https://doi.org/10.1097/SLA.0000000000000742.

    Article  PubMed  Google Scholar 

  • Launay-Vacher V, Karie S, Deray G. GPR® Anticancéreux. Guide de prescription des médicaments chez le patient insuffisant renal 3ème edn. Paris: Méditions International; 2005.

    Google Scholar 

  • Launay-Vacher V, Chatelut E, Lichtman S, Wildiers H, Steer C, Aapro M. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol. 2007a;18:1314–21.

    Article  CAS  PubMed  Google Scholar 

  • Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007b;110(6):1376–84.

    Article  CAS  PubMed  Google Scholar 

  • Launay-Vacher V, Aapro M, De Castro G Jr, Cohen E, Deray G, Dooley M, Humphreys B, Lichtman S, Rey J, Scotte F, Wildiers H, Sprangers B. Renal effects of molecular targeted therapies in oncology: a review by the cancer and the kidney international network (C-KIN). Ann Oncol. 2015;26(8):1677–84. https://doi.org/10.1093/annonc/mdv136.

    Article  CAS  PubMed  Google Scholar 

  • Lichtman SM. Therapy insight: therapeutic challenges in the treatment of elderly cancer patients. Nat Clin Pract Oncol. 2006;3(2):86–93. https://doi.org/10.1038/ncponc0420.

    Article  CAS  PubMed  Google Scholar 

  • Lichtman SM. Call for changes in clinical trial reporting of older patients with cancer. J Clin Oncol. 2012a;30(8):893–4. https://doi.org/10.1200/JCO.2011.41.0696.

    Article  PubMed  Google Scholar 

  • Lichtman SM. Clinical trial design in older adults with cancer—the need for new paradigms. J Geriatr Oncol. 2012b;3:368–75.

    Article  Google Scholar 

  • Lichtman SM. Polypharmacy: geriatric oncology evaluation should become mainstream. J Clin Oncol. 2015;33(13):1422–3. https://doi.org/10.1200/JCO.2014.60.3548.

    Article  PubMed  Google Scholar 

  • Lichtman SM, Etcubanas E, Budman DR, Eisenberg P, Zervos G, D’Amico P, O’Mara V, Musgrave K, Cascella P, Melikian A, Hinderling PH, Ferrer JM, Williams GJ. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Investig. 2002;20(7–8):904–13.

    Article  CAS  Google Scholar 

  • Lichtman SM, Hollis D, Miller AA, Rosner GL, Rhoades CA, Lester EP, Millard F, Byrd J, Cullinan SA, Rosen DM, Parise RA, Ratain MJ, Egorin MJ. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: cancer and leukemia group B (CALGB 9762). J Clin Oncol. 2006;24(12):1846–51.

    Article  CAS  PubMed  Google Scholar 

  • Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, Tranchand B, Shapira I, Aapro M. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients–an analysis of the medical literature. J Clin Oncol. 2007a;25(14):1832–43.

    Article  CAS  PubMed  Google Scholar 

  • Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007b;43(1):14–34. https://doi.org/10.1016/j.ejca.2006.11.004.

    Article  PubMed  Google Scholar 

  • Lichtman SM, Hurria A, Cirrincione CT, Seidman AD, Winer E, Hudis C, Cohen HJ, Muss HB. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol. mdr297 [pii]. 2011; https://doi.org/10.1093/annonc/mdr297.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lichtman SM, Cirrincione CT, Hurria A, Jatoi A, Theodoulou M, Wolff AC, Gralow J, Morganstern DE, Magrinat G, Cohen HJ, Muss HB. Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: Alliance A171201, an ancillary study of CALGB/CTSU 49907. J Clin Oncol. 2016;34(7):699–705. https://doi.org/10.1200/JCO.2015.62.6341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maisano R, Mare M, Caristi N, Chiofalo G, Picciotto M, Carboni R, Mafodda A, La Torre F. A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study. J Chemother. 2005;17(2):242–6.

    Article  CAS  PubMed  Google Scholar 

  • Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol. 2002;50(1):37–45.

    Article  CAS  PubMed  Google Scholar 

  • Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, Bailey DL, Harper PG. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol. 2004;15(2):291–5.

    Article  CAS  PubMed  Google Scholar 

  • Mattioli R, Massacesi C, Recchia F, Marcucci F, Cappelletti C, Imperatori L, Pilone A, Rocchi M, Cesta A, Laici G, Bonsignori M, Lippe P. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol. 2005;16(7):1147–51.

    Article  CAS  PubMed  Google Scholar 

  • McEvoy G. AHFS 2000. Drug information. Bethesda: American Society of Health System Pharmacists; 2000.

    Google Scholar 

  • Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16(11):3537–41.

    Article  Google Scholar 

  • Mick R, Gupta E, Vokes EE, Ratain MJ. Limited-sampling models for irinotecan pharmacokinetics- pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol. 1996;14(7):2012–9.

    Article  CAS  PubMed  Google Scholar 

  • Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL. Pharmacology of 21-day oral etoposide given in combination with i.v. Cisplatin in patients with extensive-stage small cell lung cancer: a Cancer and Leukemia Group B study (CALGB 9062). Clin Cancer Res. 1997;3(5):719–25.

    CAS  PubMed  Google Scholar 

  • Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Phase I and pharmacokinetic study of Pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006;24(4):552–62.

    Article  CAS  PubMed  Google Scholar 

  • Monfardini S, Aversa SM, Zoli V, Salvagno L, Bianco A, Bordonaro R, Benevolo G, Crugnola M, Crivellari G, Vivaldi P, Basso U, Torri V. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin’s lymphomas. Ann Oncol. 2005;16(8):1352–8.

    Article  CAS  PubMed  Google Scholar 

  • Montazeri A, Boucaud M, Lokiec F, Pinguet F, Culine S, Deporte-Fety R, Albin N, Laguerre B, Goupil A, Bugat R, Canal P, Chatelut E. Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol. 2000;46(5):375–81.

    Article  CAS  PubMed  Google Scholar 

  • Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33(13):1453–9. https://doi.org/10.1200/JCO.2014.58.7550.

    Article  PubMed  Google Scholar 

  • O’Reilly S, Armstrong DK, Grochow LB. Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan [letter]. Gynecol Oncol. 1997;67(3):329–30.

    Article  PubMed  Google Scholar 

  • Owen JS, Melhem M, Passarell JA, D’Andrea D, Darwish M, Kahl B. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol. 2010;66(6):1039–49. https://doi.org/10.1007/s00280-010-1254-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raghavan D, Suh T. Cancer in the elderly population: the protection racket. J Clin Oncol. 2006;24(12):1795–6.

    Article  PubMed  Google Scholar 

  • Rao AV, Cohen HJ. Preface. Clin Geriatr Med. 2016;32(1):xiii–xiv. https://doi.org/10.1016/j.cger.2015.09.001.

    Article  PubMed  Google Scholar 

  • Reece PA, Hill HS, Green RM, Morris RG, Dale BM, Kotasek D, Sage RE. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol. 1988;22(4):348–52.

    Article  CAS  PubMed  Google Scholar 

  • Reed E, Dabholkar M, Chabner BA. Platinum Analogues. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia: Lippincott-Raven; 1996. p. 357–78.

    Google Scholar 

  • Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll H-J, Douillard J-Y, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz H-J. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. J Clin Oncol. 2016;34(2):144–50. https://doi.org/10.1200/jco.2015.61.6441.

    Article  CAS  PubMed  Google Scholar 

  • Reuben DB, Rubenstein LV, Hirsch SH, Hays RD. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med. 1992;93(6):663–9.

    Article  CAS  PubMed  Google Scholar 

  • Robieux I, Sorio R, Borsatti E, Cannizzaro R, Vitali V, Aita P, Freschi A, Galligioni E, Monfardini S. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther. 1996;59(1):32–40.

    Article  CAS  PubMed  Google Scholar 

  • Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–95. https://doi.org/10.1503/cmaj.050051.

    Article  PubMed  PubMed Central  Google Scholar 

  • Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996;14(11):3000–8.

    Article  CAS  PubMed  Google Scholar 

  • Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999;85(4):786–95.

    Article  CAS  PubMed  Google Scholar 

  • Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [see comments] [published erratum appears in Lancet 1998 Nov 14;352(9140):1634]. Lancet. 1998;352(9138):1407–12.

    Article  CAS  PubMed  Google Scholar 

  • Safra T, Muggia F, Jeffers S, Tsao-Wei D, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol. 2000;11(8):p1029–33.

    Article  Google Scholar 

  • Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091–7.

    Article  CAS  PubMed  Google Scholar 

  • Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012;30(17):2036–8. JCO.2012.41.6727 [pii]. https://doi.org/10.1200/JCO.2012.41.6727.

    Article  PubMed  Google Scholar 

  • Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93(11):850–7.

    Article  CAS  PubMed  Google Scholar 

  • Seidman AD. “Will weekly work”? Seems to be so. J Clin Oncol. 2005;23(25):5873–4.

    Article  PubMed  Google Scholar 

  • Shah RR. Drug development and use in the elderly: search for the right dose and dosing regimen (parts I and II). Br J Clin Pharmacol. 2004;58(5):452–69.

    Article  PubMed  PubMed Central  Google Scholar 

  • Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer. 2006;94(7):964–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–205.

    Article  CAS  PubMed  Google Scholar 

  • Smorenburg CH, ten Tije AJ, Verweij J, Bontenbal M, Mross K, van Zomeren DM, Seynaeve C, Sparreboom A. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer. 2003;39(2):196–202.

    Article  CAS  PubMed  Google Scholar 

  • Sonnichsen DS, Relling MV. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet. 1994;27(4):256–69.

    Article  CAS  PubMed  Google Scholar 

  • Sorio R, Robieux I, Galligioni E, Freschi A, Colussi AM, Crivellari D, Saracchini S, Monfardini S. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer. 1997;33(2):301–3.

    Article  CAS  PubMed  Google Scholar 

  • Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, Lamont A, Harper PG. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997;89(8):577–80.

    Article  CAS  PubMed  Google Scholar 

  • Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995;75:11–7.

    Article  CAS  PubMed  Google Scholar 

  • Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, Brach J, Chandler J, Cawthon P, Connor EB, Nevitt M, Visser M, Kritchevsky S, Badinelli S, Harris T, Newman AB, Cauley J, Ferrucci L, Guralnik J. Gait speed and survival in older adults. J Am Med Assoc. 2011;305(1):50–8. 305/1/50 [pii]. https://doi.org/10.1001/jama.2010.1923.

    Article  CAS  Google Scholar 

  • Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol. 2003;21(14):2664–72.

    Article  CAS  PubMed  Google Scholar 

  • Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22(22):4626–31.

    Article  PubMed  Google Scholar 

  • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, the TAXI. Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  CAS  PubMed  Google Scholar 

  • Tew WP, Java J, Chi D, Menzin A, Lovecchio JL, Bookman MA, Lichtman SM. Treatment outcomes for older women with advanced ovarian cancer: results from a phase III clinical trial (GOG182). ASCO Meeting Abstracts. 2010;28(15_suppl):5030.

    Google Scholar 

  • The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91(1):66–72.

    Article  Google Scholar 

  • Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer. 2004;100(10):2052–63.

    Article  CAS  PubMed  Google Scholar 

  • Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R, Barlogie B. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2(6):947–52.

    CAS  PubMed  Google Scholar 

  • Twelves CJ, Dobbs NA, Michael Y, Summers LA, Gregory W, Harper PG, Rubens RD, Richards MA. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer. 1992;66(4):765–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Urien S, Bree F, Breillout F, Bastian G, Krikorian A, Tillement JP. Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother Pharmacol. 1993;32(3):231–4.

    Article  CAS  PubMed  Google Scholar 

  • Uyar D, Frasure HE, Markman M, von Gruenigen VE. Treatment patterns by decade of life in elderly women (>/=70 years of age) with ovarian cancer. Gynecol Oncol. 2005;98(3):403–8.

    Article  PubMed  Google Scholar 

  • VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O’Connor T, Rugo HS, Rupper RW, Shepard D, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Wildes T, Bergman MA, Sundar H, Hurria A. NCCN guidelines insights: older adult oncology, version 2.2016. J Natl Compr Cancer Netw. 2016;14(11):1357–70.

    Article  Google Scholar 

  • Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998;16:1811–9.

    Article  CAS  PubMed  Google Scholar 

  • Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000;18:2780–7.

    Article  CAS  PubMed  Google Scholar 

  • Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003;14(12):1783–90.

    Article  CAS  PubMed  Google Scholar 

  • Vigneau C, Ardiet C, Bret M, Laville M, Fiere D, Tranchand B, Fouque D. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure. J Nephrol. 2002;15(6):684–9.

    CAS  PubMed  Google Scholar 

  • Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol. 1982;9(1):23–33.

    Google Scholar 

  • Wade JR, Kelman AW, Kerr DJ, Robert J, Whiting B. Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol. 1992;29(5):391–5.

    Article  CAS  PubMed  Google Scholar 

  • Walko CM, McLeod HL. Personalizing medicine in geriatric oncology. J Clin Oncol. 2014;32(24):2581–6. https://doi.org/10.1200/JCO.2014.55.9047.

    Article  PubMed  Google Scholar 

  • Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, Curigliano G, Extermann M, Lichtman SM, Ballman K, Cohen HJ, Muss H, Wedding U. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer–Alliance for Clinical Trials in Oncology–International Society of Geriatric Oncology position article. J Clin Oncol. 2013;31(29):3711–8. https://doi.org/10.1200/jco.2013.49.6125.

    Article  PubMed  Google Scholar 

  • Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, Falandry C, Artz A, Brain E, Colloca G, Flamaing J, Karnakis T, Kenis C, Audisio RA, Mohile S, Repetto L, Van Leeuwen B, Milisen K, Hurria A. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603. https://doi.org/10.1200/JCO.2013.54.8347.

    Article  PubMed  PubMed Central  Google Scholar 

  • Williams GR, Mackenzie A, Magnuson A, Olin R, Chapman A, Mohile S, Allore H, Somerfield MR, Targia V, Extermann M, Cohen HJ, Hurria A, Holmes H. Comorbidity in older adults with cancer. J Geriatr Oncol. 2015; https://doi.org/10.1016/j.jgo.2015.12.002.

    Article  PubMed  Google Scholar 

  • Wong M, Balleine RL, Blair EY, McLachlan AJ, Ackland SP, Garg MB, Evans S, Farlow D, Collins M, Rivory LP, Hoskins JM, Mann GJ, Clarke CL, Gurney H. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol. 2006;24(16):2448–55.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Stuart Lichtman is supported in part through the NIH/National Cancer Institute Cancer Center Support Grant P30 CA008748.

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, Commack, NY, USA

    Stuart M. Lichtman

  2. Weill Cornell Medical College, New York, NY, USA

    Stuart M. Lichtman

  3. International Society of Geriatric Oncology, Geneva, Switzerland

    Stuart M. Lichtman

Authors
  1. Stuart M. Lichtman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart M. Lichtman .

Editor information

Editors and Affiliations

  1. Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL, USA

    Martine Extermann

Section Editor information

  1. Senior Adult Oncology Program, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA

    Martine Extermann

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Lichtman, S.M. (2019). Principles of Chemotherapy in Older Adults. In: Extermann, M. (eds) Geriatric Oncology . Springer, Cham. https://doi.org/10.1007/978-3-319-44870-1_14-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44870-1_14-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44870-1

  • Online ISBN: 978-3-319-44870-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation